At last month's Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It…
Nearly 30 years ago, back when your author was a humble pharmacy intern, the first therapeutic to combat HIV (azidothymidine) was introduced by Burroughs Wellcome (now part of GSK). Back…
Given that we are now in January, we feel obliged to craft some sort of "Predictions for 2016" post. We're not big fans of predictive posts, mainly because we're…
So, how did we do? This year, our fifth, was very good. By all objective measures, 2015 was our most successful year, and we want to thank all…
This morning, our friends at EBD and MacDougall Biomedical Communications presented a very good webinar on preparing for the upcoming festivities in San Francisco. In case you missed it, I…
Last week, a study published in JAMA Dermatology examined the skyrocketing prices for dermatology prescription products. Amazingly, Of the 19 brand-name drugs analyzed, the retail prices of 7 drugs more…
I love what you did with the place... It's always difficult for us to contribute any sensible overarching overview of any partnering conference, especially BIO Europe Fall. This is entirely…
We go to a lot of conferences. And, as a result, we see a lot of assets being marketed by pharma & biotech executives which will likely never find a…
Last month, EBD and IMS partnered to analyze meeting outcomes from four conferences, covering nearly 5,000 participating companies. Their report is available here (PDF). As we are knee-deep in scheduling…
Last week, we had the good fortune of spending a week in India, along with our colleagues from Ventac Partners. Our trip took us through the cities of Mumbai,…